View in EDS

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer.

Saved in:
Bibliographic Details
Title: Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer.
Authors: Gettinger, S.1, Chow, L.Q.2, Borghaei, H.3, Shen, Y.4, Harbison, C.4, Chen, A.C.4, Rizvi, N.A.5
Source: International Journal of Radiation Oncology, Biology, Physics. Nov2014 Supplement, Vol. 90 Issue 5, pS34-S35. 1p.
Subjects: Erlotinib, Medication safety, Epidermal growth factor receptors, Lung cancer treatment, Metastasis, Genetic mutation
Database: Engineering Source
Description
ISSN:03603016
DOI:10.1016/j.ijrobp.2014.08.210